This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The U.S. FDA approved reteplase on Oct 30, 1996. Reteplase is a thrombolytic agent that helps to break up a blood clot and restores blood flow.

Mechanism of Action of undefined

The main activity of the drug is to increase the breakdown of  the blood clot by  increasing the breakdown of the blood clotting enzyme (plasminogen).

Uses of undefined

It is used to dissolve a blood clot that causes a heart attack (Acute Myocardial Infarction) within 12 hours of symptoms arising.

undefined Drug administaration and Dosage available

Reteplase is available as syringes in an 18 mg injection which is administered into the veins by your doctor. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the medicine if your doctor advises you to stop.

Warnings, Precautions and Side Effects of undefined

Warnings

Individuals who are taking heparin and aspirin (acetylsalicylic acid) should inform your doctor. Otherwise, it may cause excessive bleeding. If you have a bleeding disorder, ulcer in the stomach or small intestine, enlarged blood vessels in food pipes, or high blood pressure, discuss your previous medical history before taking the medicine.

Precautions

A patient with problems such as a brain disorder, bleeding disorder, High blood pressure, or Kidney and liver disorder should consult their doctor before taking medicine. It is necessary to inform your doctor if you have been undergoing major surgery for the past three months.Inform your doctor if your Pregnant or breastfeeding women. Even though there is no clinical evidence regarding passage of the drug through the breast milk, it is better to inform your doctor to avoid any potential side effects.

Side Effects

The common side effects that are experienced while you are on the treatment with reteplase injection are bleeding at the injection site, pain in chest, recurrent ischaemia (reduction in the blood supply), heart failure, pulmonary oedema, low blood pressure, shortness of breath, burning sensation, bleeding in the digestive tract (blood vomiting), urinary tract, gums, abnormal heart function (arrhythmias).

Word Of Advice

Before taking the medication, it's essential to discuss your medical history if you have a bleeding disorder, stomach or small intestine ulcers, enlarged blood vessels in the food pipes, or high blood pressure. The blood pressure of the patient should be monitored before administering the medicine to avoid complications caused by the drug. You can apply gentle pressure to avoid bleeding at the injection site.

Frequently Asked Question

References

  1. Actavis Italy S.p.A, European Medicines agency (EMA), [Revised on February 2006][ Accessed Feb 2024], https://www.ema.europa.eu/en/documents/product-information/rapilysin-epar-product-information_en.pdf
  2. Actavis Italy S.p.A, European Medicines agency (EMA), [Revised on February 2016][ Accessed Feb 2024], Rapilysin, INN-reteplase (europa.eu)
  3. Reliance lifescience; [Accessed on 15/02/2024]; https://www.rellife.com/web/lifesciences/mirel
  4. KD Tripathi, Essentials of Medical Pharmacology, Adrenergic system and drugs, 7th edition, 2013, 134.
  5. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs, 12th edition, 2011, 866.

Disclaimer

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.